Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model Cifurtilimab - ...

MedChemExpress - Model Cifurtilimab - 1629760-27-5

Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities[1][2].

Cifurtilimab

MCE China：Cifurtilimab

Brand：MedChemExpress (MCE)

Cat. No.HY-P99603

CAS：1629760-27-5

Synonyms：SEA-CD40

Purity：95.00%

Storage：Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping：Shipping with dry ice.

Description：Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities.

In Vitro：Cifurtilimab has enhanced FcγRIIIa binding (~10x greater than parent IgG1 antibody) that drives increased effector function, resulting in more potent immune stimulatory activity than antibodies with muted or selective FcγR binding[1]. Cifurtilimab exposure results in a distinct signature of responses including activation of APCs, CD8+ and CD4+ T cells and NK cells, and targeted depletion of CD40+ B cells[1].

In Vivo：In preclinical mouse models, Cifurtilimab combined with chemotherapeutic agents to drive robust anti-tumor activity[2].

IC50 & Target：CD40[1] In Vitro Cifurtilimab has enhanced FcγRIIIa binding (~10x greater than parent IgG1 antibody) that drives increased effector function, resulting in more potent immune stimulatory activity than antibodies with muted or selective FcγR binding[1]. Cifurtilimab exposure results in a distinct signature of responses including activation of APCs, CD8+ and CD4+ T cells and NK cells, and targeted depletion of CD40+ B cells[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Cifurtilimab Related Antibodies

Species：Human

Isotype：Human IgG1 kappa

Recommend Isotype Controls：Human IgG1 kappa, Isotype Control

References：

[1]. Neff-LaFord H, et al. SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors. Cancer Research, 2020, 80(16_Supplement): 5535-5535.

[2]. Zeng W, et al. 438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models. 2020.

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。